专题：专题|2024年度A股董秘数据报告：1144位董秘年薪超百万 占比超21% 董秘作为连接投资者与上市公司的"桥梁"，在上市公司资本运作中发挥着关键作用。新浪财经《2024年 度A股董秘数据报告》显示，2024年A股上市公司董秘薪酬合计达40.86亿元，平均年薪75.43万元。 分行业来看，统计数据显示，A股共有69家上市中药公司，董事会秘书聘任总体情况如下（部分统计口 径剔除无效数据）。 从董秘的年龄分布来看，介于40-50岁的董秘是市场的中坚力量，占比达到42%；50岁以上的董秘占比 为29%；小于40岁的董秘群体占比为26%。其中，最年轻的上市公司董秘年仅32岁，为特一药业的许紫 兰。 从董秘的学历分布看，拥有大专、本科、硕士、博士学历的董秘占比分别为5%、42%、49%、4%，硕 士及以上学历董秘占比已超过半数。其中，获得博士学历的董秘仅三人，分别为以岭药业（维权）的吴 瑞、昆药集团的张梦珣、金花股份（维权）的张朝阳。 从薪酬分布看，A股中药上市公司董秘年薪平均值为74.24万元。经统计，处于50万以下、50万-100万、 100万-200万、200万-300万、300万以上各区间的人数分别为27 ...

[Current Period Performance Forecast](index=1&type=section&id=I.%20Current%20Period%20Performance%20Forecast) The company forecasts a loss for the first half of 2025, with a significant narrowing of the loss compared to the same period last year, projecting net profit attributable to shareholders between -21.24 million CNY and -17.70 million CNY, based on unaudited preliminary results Key Financial Indicators Forecast | Indicator | Estimated Amount (CNY) | | :--- | :--- | | Net Profit Attributable to Parent Company Shareholders | -21.24 million to -17.70 million | | Net Profit After Non-Recurring Gains and Losses | -33.36 million to -27.80 million | - This performance forecast is unaudited by a certified public accountant[4](index=4&type=chunk) [Operating Performance and Financial Status for the Same Period Last Year](index=1&type=section&id=II.%20Operating%20Performance%20and%20Financial%20Status%20for%20the%20Same%20Period%20Last%20Year) For comparison, the company reported a net loss of -106.49 million CNY and a non-recurring adjusted net loss of -111.54 million CNY for the first half of 2024, with basic earnings per share at -0.134 CNY Key Financial Indicators for H1 2024 | Indicator | H1 2024 Amount (CNY) | | :--- | :--- | | Net Profit Attributable to Parent Company Shareholders | -106.49 million | | Net Profit After Non-Recurring Gains and Losses | -111.54 million | | Earnings Per Share | -0.134 | [Primary Reasons for Current Period's Expected Loss](index=2&type=section&id=III.%20Primary%20Reasons%20for%20Current%20Period's%20Expected%20Loss) The core reason for the continued loss is a 15% projected decrease in revenue due to reduced sales of main products, yet effective cost and expense control, with an estimated 20% reduction, has narrowed the overall loss compared to the prior year - The primary reason for the expected loss is the impact of core business operations, with main product sales decreasing, leading to an estimated **15% decline in revenue**[7](index=7&type=chunk) - Despite the revenue decline, costs and expenses decreased more significantly, with an estimated **20% reduction**, resulting in a smaller loss for the current period compared to the prior year[7](index=7&type=chunk) [Risk Warning](index=2&type=section&id=IV.%20Risk%20Warning) The company emphasizes that this performance forecast is based on preliminary internal calculations and is unaudited, but confirms no significant uncertainties affect its accuracy - This performance forecast is a preliminary calculation by the company's finance department and has not yet been audited[8](index=8&type=chunk) - The company states there are no significant uncertainties affecting the accuracy of this performance forecast[8](index=8&type=chunk) [Other Explanatory Matters](index=2&type=section&id=V.%20Other%20Explanatory%20Matters) The company reminds investors that the final accurate financial data will be based on the officially disclosed 2025 semi-annual report, and advises caution regarding investment risks - The final financial data will be subject to the company's officially disclosed 2025 semi-annual report[9](index=9&type=chunk)

益佰制药（600594）公告，预计2025年半年度实现归属于母公司所有者的净利润为-2124万元到-1770万 元，将出现亏损。公司预计2025年半年度实现归属于母公司所有者的扣除非经常性损益后的净利润 为-3336万元到-2780万元。 ...

Core Viewpoint - The ongoing issues of commercial bribery in the biopharmaceutical sector are highlighted, with specific focus on Yibai Pharmaceutical's involvement and regulatory scrutiny [1][3]. Company Overview - Yibai Pharmaceutical (600594.SH) is a modern Chinese medicine company focusing on the research, production, and sales of products targeting oncology, gynecology, and cardiovascular diseases. The company was listed on the A-share market in 2004 [2][8]. Financial Performance - Yibai Pharmaceutical has faced operational challenges in recent years, with two years of losses from 2020 to 2024 and a declining revenue trend. The company's revenue decreased from 34.13 billion to 21.74 billion from 2020 to 2024, with net profits showing significant fluctuations, including a total loss of 1.88 billion over five years [9][10][11]. - In Q1 2024, the company reported a revenue of 5.01 billion, a year-on-year decline of 12.43%, and a net profit of -0.09 billion, despite an 86.29% reduction in losses compared to the previous year [11]. Regulatory Issues - Yibai Pharmaceutical has been frequently scrutinized for regulatory violations, including issues related to information disclosure and operational compliance. In 2024, the company and its executives received multiple warnings from regulatory bodies for failing to disclose significant operational impacts [12][13]. - The company was included in a list of 25 pharmaceutical firms involved in commercial bribery, as reported by the Anhui Provincial Medical Procurement Platform [3][4]. Marketing and R&D Expenditure - The company's marketing expenses have been notably high, with 2023 and 2024 marketing costs around 9 billion each, raising concerns about potential commercial bribery. The sales expense ratio was approximately 43.89% in 2023 and 50.46% in 2024, with a significant portion allocated to academic promotion and marketing platform construction [6][8]. - In contrast, Yibai Pharmaceutical's R&D investment has been declining, with expenditures dropping from 2.20 billion in 2017 to 1.01 billion in 2024, indicating a lack of focus on innovation compared to marketing efforts [7][8].

Group 1 - The article highlights the exposure of several pharmaceutical companies, including Yibai Pharmaceutical, China Resources Pharmaceutical, and Haiwang Bio, for involvement in medical commercial bribery cases [2] - The Anhui Provincial Medical Procurement Platform announced a credit rating disposal related to these bribery cases, affecting companies such as Yibai Pharmaceutical and its subsidiaries [2] - Yibai Pharmaceutical's main business segments include pharmaceutical manufacturing, medical services, and the health industry, covering various therapeutic areas such as oncology and cardiovascular diseases [2] Group 2 - Yibai Pharmaceutical's 2024 annual report indicates that its oncology drugs generated the highest revenue, amounting to 612 million yuan, with a gross margin of 88.38% [3] - The company reported a decrease in sales expenses to 1.097 billion yuan, down 11.44% year-on-year, accounting for 50.45% of total revenue [3] - Research and development expenses for Yibai Pharmaceutical in 2024 were 100 million yuan, a decline of 10.38%, representing 4.62% of annual revenue [3] Group 3 - In 2024, Yibai Pharmaceutical faced production suspension due to violations of drug production quality management standards, specifically concerning its Aidi injection product [4] - The Aidi injection, which has applications in treating various cancers, sold over 29 million units in 2023 [4]

Core Viewpoint - The article highlights the emergence of a notable individual investor, Zhang Sufen, in the A-share market, who has made significant investments in multiple listed companies, positioning herself among the top shareholders of 15 companies as of the first quarter of 2025 [1][2][3]. Group 1: Investment Profile - Zhang Sufen holds substantial shares in various companies, with a total holding of 349.66 million shares across 15 listed companies, making her the second-largest shareholder in Electronic City and the fourth-largest in Shaanxi Guotou A [3][4]. - Her investment strategy appears to focus on low-priced stocks, with most of her holdings priced below 10 yuan, indicating a preference for undervalued assets [7][8]. - The total market value of her holdings exceeds 1.38 billion yuan, with five stocks valued over 100 million yuan each [8]. Group 2: Performance and Strategy - Zhang's investments have shown mixed results, with the highest floating profit being 26.81% from Liugang Co., while the largest loss is 13.62% from Shaanxi Construction [3][4]. - She has demonstrated a long-term investment approach, often increasing her holdings over several quarters, as seen in her continuous accumulation of shares in low-performing stocks like New Star Foundry [6][7]. - Despite her success, she has also faced significant losses, such as a 30% loss in Yibai Pharmaceutical, highlighting the risks associated with her investment choices [8][9]. Group 3: Market Impact and Perception - Zhang Sufen's investment activities have drawn attention in the market, with speculation about her potential connections to larger investment networks, suggesting that her strategies may not be typical of individual investors [7][8]. - Her approach to investing, characterized by a focus on low-priced stocks and a willingness to endure volatility, positions her as a unique figure in the A-share market, comparable to institutional investors [6][7].

北京市君致律师事务所 关于贵州益佰制药股份有限公司 2024 年 年度股东大会 法 律 意 见 书 北京市东城区北三环东路 36 号环球贸易中心Ｂ座 11 层 邮编(100013) Add: 11/F, Tower B, Global Trade Center, No.36 North Third Ring Road East, Dongcheng District, Beijing, 100013, PRC Tel: 010-52213236/7 www.junzhilawyer.com 北京市君致律师事务所 关于贵州益佰制药股份有限公司 2024 年年度股东大 会法律意见书 致:贵州益佰制药股份有限公司 北京市君致律师事务所(以下简称"本所")接受贵州益佰制药股份有限公 司(以下简称"益佰制药"或"公司")的委托,指派律师出席益佰制药 2024 年 年度股东大会（以下简称"本次股东大会")。根据《中华人民共和国证券法》(以 下简称"《证券法》"）、《中华人民共和国公司法》(以下简称"《公司法》")和《上 市公司股东大会规则》(以下简称"《股东大会规则》"、《上海证券交易所上市 公司自律监管指引第1号一规范 ...

证券代码：600594 证券简称：益佰制药 公告编号：2025-018 贵州益佰制药股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东大会召开的时间：2025 年 5 月 16 日 (二)股东大会召开的地点：贵州益佰制药股份有限公司行政楼办公室 2、 公司在任监事3人，出席3人； (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 219 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 192,435,471 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份总数的比例（%） | 24.5330 | (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，副董事长窦雅琪女士主持，会议采用现 场投票与网络投票相结合的方式进行表决，本次会议的召集、召开和表决 ...

Core Viewpoint - Yibai Pharmaceutical has faced significant financial challenges due to the suspension of its exclusive product, Aidi Injection, leading to a substantial decline in revenue and a net loss in 2024 [2][7]. Financial Performance - In 2024, Yibai Pharmaceutical reported total revenue of 2.174 billion, a decrease of 22.92% compared to the previous year [3][7]. - The net profit attributable to shareholders was a loss of 317.22 million, marking a 406.79% decline year-on-year [3][7]. - The net cash flow from operating activities fell by 76.99% to 86.87 million [3]. - The pharmaceutical industrial segment's revenue dropped by 28.36% to 1.684 billion, primarily due to the impact of the suspension of Aidi Injection [7]. Product and Market Impact - Aidi Injection, a key product for Yibai Pharmaceutical, has seen a decline in revenue over recent years, with sales dropping from 7.37 billion in 2020 to 4.73 billion in 2023 [12]. - The suspension of Aidi Injection has led to the loss of its selected status in centralized procurement, resulting in an estimated revenue loss of approximately 499 million from 2020 to 2023 [6]. Recovery Efforts - Yibai Pharmaceutical has completed internal rectification related to the production issues and is in discussions with regulatory authorities to resume production of Aidi Injection [2][6]. - The company reported a slight recovery in the first quarter of 2025, with revenue of 501 million, a decrease of 12.43% year-on-year, and a reduced net loss compared to the previous year [8]. R&D and Future Strategy - Despite financial pressures, Yibai Pharmaceutical has maintained its commitment to R&D, with a reported R&D expenditure of 100.5 million in 2024, although this represents a 10.38% decrease from the previous year [12][14]. - The company is focusing on diversifying its product line and enhancing its R&D capabilities to reduce reliance on single products [14].

贵州益佰制药股份有限公司 2024 年年度股东大会会议资料 贵州益佰制药股份有限公司 600594 2024年年度股东大会会议资料 1/23 贵州益佰制药股份有限公司 2024 年年度股东大会会议资料 目录 | 贵州益佰制药股份有限公司 2024 年年度股东大会会议议程 3 | | | --- | --- | | 议案一：《公司 年年度董事会工作报告》 5 | 2024 | | 议案二：《公司 年年度监事会工作报告》 8 | 2024 | | 议案三：《公司 年年度财务决算报告》 11 | 2024 | | 议案四：《公司 年年度利润分配预案》 14 | 2024 | | 议案五：《公司 年年度报告全文及其摘要》 16 | 2024 | | 议案六：《关于续聘公司 2025 年年度审计机构的议案》 17 | | | 议案七：《关于公司及其控股子公司申请 2025 年年度银行综合授信额度的议 | | | 案》 20 | | | 议案八：《关于公司未来三年（2025-2027 年）股东回报规划的议案》 21 | | 2/23 贵州益佰制药股份有限公司 2024 年年度股东大会会议资料 贵州益佰制药股份有限公司 2 ...